Table 1.
Characteristics of the study population, classified by HbA1c profile and monitoring completeness
|
HbA1c profile 1*
Target HbA1c: 53 mmol/mol (7.0%) |
HbA1c profile 2†
Target HbA1c: 58 mmol/mol (7.5%) |
HbA1c profile 3‡
HbA1c: 64 mmol/mol (8.0%) |
|||||
|
Incomplete
n=3345 |
Complete
n=6794 |
Incomplete
n=396 |
Complete
n=656 |
Incomplete
n=217 |
Complete
n=687 |
||
| HbA1c level: mean (SD) | mmol/mol | 53.51 (12.31) | 51.56 (10.51) | 55.91 (11.66) | 53.87 (10.60) | 55.12 (10.57) | 53.60 (8.98) |
| % | 7.05 (1.13) | 6.87 (0.96) | 7.27 (1.07) | 7.08 (0.97) | 7.19 (0.97) | 7.06 (0.82) | |
| Diabetes duration, years: median (IQR) | 3 (3–8) | 7 (4–10) | 3 (3–7) | 7 (4–8) | 13 (11–16) | 13 (11–15) | |
| Age (years): median (IQR) | 61 (54–67) | 62 (55–68) | 74 (72–76) | 74 (71–76) | 74 (72–77) | 74 (72–76) | |
| Gender: % women (n) | 44 (1465) | 46 (3106) | 46 (183) | 45 (297) | 51(110) | 46 (316) | |
*Profile 1: patients aged <70 years, and older patients with a mild treatment regime (only metformin monotherapy prescription).
†Profile 2: patients aged ≥70 years who need more intensive treatment and diagnosed with diabetes <10 years ago.
‡Profile 3: patients aged ≥70 years who need more intensive treatment and diagnosed with diabetes ≥10 years ago.